Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer

1. Kikuchi A, Yamamoto H, Sato A. Selective activation mechanisms

of Wnt signaling pathways. Trends Cell Biol. 2009;19:119–29.

2. Cao Y, Wang X, Xu C, Gao Z, Zhou H, Wang Y, et al. 4-HPR

impairs bladder cancer cell migration and invasion by interfering with the Wnt5a/JNK and Wnt5a/MMP-2 signaling pathways.

Oncol Lett. 2016;12:1833–9.

3. Kurayoshi M, Oue N, Yamamoto H, Kishida M, Inoue A, Asahara

T, et al. Expression of Wnt-5a is correlated with aggressiveness

of gastric cancer by stimulating cell migration and proliferation.

Cancer Res. 2006;66:10439–48.

4. Huang C-L, Liu D, Nakano J, Ishikawa S, Kontan K, Yokomise H,

et al. Wnt5a expression is associated with the tumor proliferation

and the stromal vascular endothelial growth factor: an expression

in non–small-cell lung cancer. J Clin Oncol. 2005;23:8765–73.

5. Yamamoto H, Oue N, Sato A, Hasegawa Y, Yamamoto H, Matsubara A, et al. Wnt5a signaling is involved in the aggressiveness

of prostate cancer and expression of metalloproteinase. Oncogene.

2010;29:2036–46.

6. Kremenevskaja N, von Wasielewski R, Rao AS, Schöfl C, Andersson T, Braban G. Wnt-5a has tumor suppressor activity in thyroid

carcinoma. Oncogene. 2005;24:2144–54.

7. Bitler BG, Nicodemus JP, Li H, Cai Q, Wu H, Hua X, et al. Wnt5a

suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res. 2011;71:6184–94.

8. Kobayashi Y, Kadoya T, Amioka A, Hanaki H, Sasada S, Masumoto N, et al. Wnt5a-induced cell migration is associated with

the aggressiveness of estrogen receptor-positive breast cancer.

Oncotarget. 2018;9:20979–92.

9. Peng C, Zhang X, Yu H, Wu D, Zheng J. Wnt5a as a predictor in

poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer. Int J Gynecol Cancer. 2011;21:280–8.

10. Miller TW, Hennessy BT, González-Angulo AM, Fox EM,

Mills GB, Chen H, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in

estrogen receptor-positive human breast cancer. J Clin Invest.

2010;120:2406–13.

11. Yang SX, Polley E, Lipkowitz S. New insights on PI3K/AKT

pathway alterations and clinical outcomes in breast cancer. Cancer

Treat Rev. 2016;45:87–96.

12. Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong

EWT, Martelli AM, et al. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response

to radiation in breast cancer cells. Cell Cycle. 2011;10:3003–15.

13. Cizkova M, Cizeron-Clairac G, Vacher S, Susini A, Andrieu

C, Lidereau R, et al. Gene expression profiling reveals new

aspects of PIK3CA mutation in ER alpha-positive breast cancer:

Major implication of the Wnt signaling pathway. PLoS ONE.

2010;5:e15647.

14. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant.

2013;48:452–8.

15. Yasuda K, Ranade A, Venkataramanan R, Strom S, Chupka J,

Ekins S, et al. A comprehensive in vitro and in silico analysis of

antibiotics that activate pregnane X receptor and induce CYP3A4

in liver and intestine. Drug Metab Dispos. 2008;36:1689–97.

16. Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C,

et al. Association of genetic variation in tamoxifen-metabolizing

enzymes with overall survival and recurrence of disease in breast

cancer patients. Breast Cancer Res Treat. 2005;91:249–58.

13

17. Jia Y, Domenico J, Swasey C, Wang M, Gelfand EW, Lucas JJ.

Modulated expression of genes encoding estrogen metabolizing

enzymes by G1-phase cyclin-dependent kinases 6 and 4 in human

breast cancer cells. PLoS ONE. 2004;9:e97448.

18. Sengelaub CA, Navrazhina K, Ross JB, Halberg N, Tavazoie

SF. PTPRN2 and PLCβ1 promote metastatic breast cancer cell

migration through PI(4,5)P2-dependent actin remodeling. EMBO

J. 2016;35:62–76.

19. Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S,

Martincorena I, et al. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell. 2017;32(169–184):e7.

20. Starlard-Davenport A, Kutanzi K, Tryndyak V, Word B, Lyn-Cook

B. Restoration of the methylation status of hypermethylated gene

promoters by microRNA-29b in human breast cancer: a novel

epigenetic therapeutic approach. J Carcinog. 2013;12:15.

21. Coller JK, Krebsfaenger N, Klein K, Endrizzi K, Wolbold R, Lang

T, et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxytamoxifen in human liver. Br J Clin Pharmacol. 2002;54:157–67.

22. Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo M, Relling MV, et al. Variability in human cytochrome P450 paclitaxel

metabolism. J Pharmacol Exp Ther. 1995;275:566–75.

23. Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes

P-450 2B and 3A in human liver microsomes. Cancer Res.

1993;53:5629–37.

24. Robert J. Clinical pharmacokinetics of epirubicin. Clin Pharmacokinet. 1994;26:428–38.

25. Ichikawa W. Prediction of clinical outcome of fluoropyrimidinebased chemotherapy for gastric cancer patients, in terms of the

5-fluorouracil metabolic pathway. Gastric Cancer. 2006;9:145–55.

26. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S,

et al. High frequency of mutations of the PIK3CA gene in human

cancers. Science. 2004;304:554.

27. Kim S, Chun SY, Kwon YS, Nam KS. Crosstalk between Wnt

signaling and Phorbol ester-mediated PKC signaling in MCF-7

human breast cancer cells. Biomed Pharmacother. 2016;77:114–9.

28. Civenni G, Holbro T, Hynes NE. Wnt1 and Wnt5a induce cyclin

D1 expression through ErbB1 transactivation in HC11 mammary

epithelial cells. EMBO Rep. 2003;4:166–71.

29. Pukrop T, Klemm F, Hagemann T, et al. Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines.

Proc Natl Acad Sci USA. 2006;103:5454–9.

30. Yiu GK, Kaunisto A, Chin YR, Toker A. NFAT promotes carcinoma invasive migration through glypican-6. Biochem J.

2011;440:157–66.

31. Network CGA. Comprehensive molecular portraits of human

breast tumours. Nature. 2012;490:61–70.

32. Deng L, Chen J, Zhong XR, Luo T, Wang YP, Huang HF, et al.

Correlation between activation of PI3K/AKT/mTOR pathway

and prognosis of breast cancer in Chinese women. PLoS ONE.

2015;10:e0120511.

33. Hanaki H, Yamamoto H, Sakane H, Matsumoto S, Ohdan H, Sato

A, et al. An anti-Wnt5a antibody suppresses metastasis of gastric

cancer cells in vivo by inhibiting receptor-mediated endocytosis.

Mol Cancer Ther. 2012;11:298–307.

Publisher’s Note Springer Nature remains neutral with regard to

jurisdictional claims in published maps and institutional affiliations.

Breast Cancer

https://doi.org/10.1007/s12282-021-01268-3

CORRECTION

Correction to: Effect of Wnt5a on drug resistance in estrogen

receptor-positive breast cancer

Ai Amioka1 · Takayuki Kadoya1 · Satoshi Sueoka1 · Yoshie Kobayashi1 · Shinsuke Sasada1 · Akiko Emi1 ·

Norio Masumoto1 · Masaoki Ito1 · Koh Nakayama2 · Morihito Okada1

© The Japanese Breast Cancer Society 2021

Correction to: Breast Cancer

https://doi.org/10.1007/s12282-021-01241-0

In the original publication of the article, the first sentence

in the heading “Conclusions” in “Abstract” section should

be changed as “In ER-positive breast cancer, Wnt5a upregulates the CYP metabolic pathway and decrease the sensitivity to tamoxifen, paclitaxel, and cyclophosphamide, all of

the three, standard treatment methods for ER-positive breast

cancer.”

Publisher’s Note Springer Nature remains neutral with regard to

jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at https://doi.org/10.1007/

s12282-021-01241-0.

* Takayuki Kadoya

takayukikadoya@gmail.com

Department of Surgical Oncology, Research Institute

for Radiation Biology and Medicine, Hiroshima University,

1-2-3 Kasumi, Minami-Ku, Hiroshima 734-8551, Japan

Oxygen Biology Laboratory, Medical Research Institute,

Tokyo Medical and Dental University, Bunkyo-ku,

Tokyo 113-8510, Japan

13

Vol.:(0123456789)

...